Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DX0CJL
|
||||
| Drug Name |
4-(neopentylamino)-5-(3-(pyridin-3-yloxy)prop-1-ynyl)pyrimidine-2-carbonitrile
|
||||
| Synonyms |
CHEMBL261673
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C18H19N5O
|
||||
| Canonical SMILES |
CC(C)(C)CNc1nc(ncc1C#CCOc2cccnc2)C#N
|
||||
| InChI |
InChI=1S/C18H19N5O/c1-18(2,3)13-22-17-14(11-21-16(10-19)23-17)6-5-9-24-15-7-4-8-20-12-15/h4,7-8,11-12H,9,13H2,1-3H3,(H,21,22,23)
|
||||
| InChIKey |
CQKATIOOXAEWAB-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Cathepsin K | Target Info | [1587926] | ||
| Cathepsin L | Target Info | [1587926] | |||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Trafficking and processing of endosomal TLR | |||||
| MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| MHC class II antigen presentation | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.